Instem appoints new chief financial officer
STAFFORDSHIRE-based Instem, a leading supplier of IT solutions to the early development healthcare market, has appointed a senior audit manager from KPMG as its new chief financial officer.
The appointment of Nigel Goldsmith, who has a wealth of experience in senior financial roles at both public and private sector companies in the pharmaceutical industry, is with immediate effect
Phil Reason, chief executive of AIM-listed Instem, said: “We are confident that Nigel will be a great addition to the Instem team. At a time when we are seeking to be acquisitive Nigel’s experience in this area and also of the pharmaceutical industry will be invaluable. I would also like to take this opportunity to thank Non-Executive Director David Sherwin for standing in as Finance Director during the interim period.”
In his most recent role, Mr Goldsmith was financial director of mobile phone recycler Eazyfone and prior to that he was FD at IS Pharma – now Sinclair IS Pharma following its merger earlier this year.
During his three years with the UK-based pharmaceutical and medical device company, he oversaw two oversubscribed equity fundraisings and completed two corporate acquisitions; one in the UK and one in Switzerland.
After qualifying as a chartered accountant, he spent more than nine years at KPMG including two years as Senior Manager in Audit, prior to moving into industry.
Posts in industry also include; a seven-year tenure as CFO at Almedica International Inc, a privately held supplier of clinical trial materials to the pharmaceutical and biotech industry in Europe and the US. While at Almedica, the company grew revenues and profits in both its UK and US trading operations prior to a successful disposal in September 2005 to a private equity backed US trade buyer, Aptuit Inc, and; two years as European Controller for the sales and marketing division of laboratory equipment manufacturer, Life Sciences International.
